

## Hull and East Riding Prescribing Committee Minutes –CONFIRMED

|                              |  |
|------------------------------|--|
| <b>Date / Time</b>           | Wednesday 27 <sup>th</sup> May 2015                                      |
| <b>Venue</b>                 | The Board Room, Health House, Willerby.                                  |
| <b>Chair</b>                 | Mrs J Lyon, Head of Medicines Management , North Yorks & Humber CSU      |
| <b>Notes / Action Points</b> | Mrs W Hornsby, Senior Pharmacy Technician – Formulary/Interface, HEY.    |
| <b>Quorate: Yes / No</b>     | No – all decisions highlighted in yellow to be agreed by Hull and ER CCG |

|                   |  |
|-------------------|--|
| <b>Attendance</b> | Dr M Miller, Senior Principal Pharmacist - Interface, HEY.<br>Mr G Hill, Senior Pharmacist, CHCP<br>Dr A Jeffreys, General Practitioner, LMC.<br>Mrs J Clark, Chief Officer, Local Pharmaceutical Committee<br>Mr W Chong, Chief Pharmacist, HFT.<br>Prof A Morice, Professor of Respiratory Medicine<br>Dr S Roberts, Medical Secretary, Secretariat for Humberside LMC<br>Mrs J Moore, Non Medical Prescribing Lead, HFT<br>Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics ,HEY<br>Ms J Stark, Principal Pharmacist, Clinical Services, HFT<br>Dr Miemie Kyaing, Consultant, HFT (1.55 onwards) |
|-------------------|--|

|                  |   |
|------------------|---|
| <b>Apologies</b> | Mr S Gaines, Senior Principal Pharmacist, HEY |
|------------------|---|

| Agenda No  | Item                                   | Discussion   | Decision Made  | Action   | Lead                                | Due Date/Date complete                            |
|------------|--|--|--|--|-------------------------------------|---|
| 2015.05.01 | <b>Apologies</b>                       | As above.<br>JLy informed the committee that Dr Witvliet would be stepping down as a GP Prescribing lead for the Hull CCG and would therefore not be attending any further HERPC meetings. Therefore JLy will have to inform both CCG's of any decisions made for approval as the committee is not quorate.  | Decisions requiring CCG approval to be highlighted in yellow.  | JLy to discuss decisions with both Hull and ER CCG for final approval, and highlight the importance of filling these critical appointments | JLy                                 | July 15   |
| 2015.05.02 | <b>Declarations of Interest</b>        | DC announced he had attended a lipid panel which may be relevant as lipid guidelines were on the agenda for discussion.  | No further action  |  |                                     | May 15  |
| 2015.05.03 | <b>Minutes of the previous meeting</b> | Page 6 stated that SR would ask for feedback from CCG's on testosterone leaflet. To be changed to MM to write leaflet.   | WH to update minutes and tracker reflecting change.  |  | WH                                  | July 15   |
| 2015.05.04 | <b>Action Tracker</b>                  | <u>Pregabalin – Gabapentin</u><br>Chronic guideline on agenda for discussion<br><br><u>Communication Received – Multi-compartment aids</u><br>Working group set up to take forward. Due date for guidelines changed to Sept 15<br><br><u>Red Classification</u><br>RED drug matrix completed and on agenda for discussion<br><br><u>Traffic Light Status</u><br>Pollinex Quatro still to be discussed by CCG | Action complete<br><br>Change due date on tracker<br><br>Action complete<br><br>To be discussed at JLy board meeting | No further action<br><br>No further action   | JLy<br><br>JLy<br><br>MM<br><br>JLy | May 15<br><br>Sept 15<br><br>May 15<br><br>Mar 15 |

| Agenda No | Item | Discussion   | Decision Made   | Action            | Lead | Due Date/Date complete |
|-----------|------|--|-----------------|-------------------|------|------------------------|
|           |      | <u>Ketamine</u><br>JLy has written draft statement covering current cohort of patients.  | Action complete | No further action | JLy  | May 15                 |
|           |      | <u>Shared Care Framework Discharge and Referral</u><br>JLy has been unable to meet with contracting as there have been issues with staff leaving.  | Ongoing         |                   | JLy  | May 15                 |
|           |      | <u>SCF &amp; PG</u><br>B12 prescribing guideline has been written and is now on the website.   | Action complete | No further action | MM   | Mar 15                 |
|           |      | <u>Anticoagulant Guideline</u><br>Meeting has taken place with all relevant parties and papers are on agenda for discussion.   | Action complete | No further action | MM   | May 15                 |
|           |      | <u>Traffic Light Status</u><br>RED list has been updated   | Action complete | No further action | WH   | May 15                 |
|           |      | <u>Traffic Light Status</u><br>A CSU TAG has been drafted for Tapentadol and has been sent to EB/WC and Dr Sampu for comments.   | Action complete | No further action | JLy  | May 15                 |
|           |      | <u>TAG</u><br>MM has circulated draft ED guideline   | Action complete | No further action | MM   | May 15                 |
|           |      | <u>PG/SCF – substance misuse shared care</u><br>Public Health SCF- Hull City Council have contracted 6months advice from CSU, JLy to liaise with Nicky Bush regarding ER. JLy still to discuss the need for commissioning with both councils and confirm approval for updated SCFs | Ongoing         |                   | JLy  | May 15                 |
|           |      | <u>PG/SCF</u>  | Action complete | No further action | MM   | May 15                 |

| Agenda No  | Item   | Discussion  | Decision Made   | Action  | Lead                 | Due Date/Date complete      |
|------------|--|---|---|---|----------------------|-----------------------------|
|            |  | <p>Draft testosterone SCF has been written in line with committees comments.</p> <p><u>PG/SCF</u><br/>Nalmefene has been added to the RED list</p> <p><u>PG/SCF</u><br/>JLy has spoken to the CCGs regarding the ECG issues but currently there is no funding available to commission service in primary care.</p>  | <p>Action complete</p> <p>Action complete</p>   | <p>No further action</p> <p>No further action</p> | <p>WH</p> <p>JLy</p> | <p>May 15</p> <p>May 15</p> |
| 2015.05.05 | <b>Traffic light status</b>                      | <p>Secukinumab for the treatment of Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, to be reviewed when NICE TA published. No CSU TAG for this treatment but as no financial impact for CCG for patients initiated prior to NICE, agreed as Red.</p> <p>Daclatasvir for the treatment of Hepatitis C in combination with sofosbuvir. NHS England commissioner.</p> | <p>Approved as RED</p> <p>Approve as RED</p>  | <p>WH to update internet</p>                      | <p>WH</p>            | <p>July 15</p>              |
| 2015.05.06 | <b>Proposed Update of RED/Amber list</b>         | <p>MM has completely updated RED list to include monitoring and commissioning information</p>   | <p>New RED list to be added to website</p>  | <p>WH to update internet</p>                      | <p>WH</p>            | <p>July 15</p>              |
| 2015.05.07 | <b>Lorenzo Implementation</b>                    | <p>Claire Norfolk, CSU and MM circulated new templates for Immediate Discharge Summary which will be used when the Lorenzo system goes live on 8<sup>th</sup> June. The template was designed in conjunction with primary care. The new IDS will still be faxed to GP surgeries but it is anticipated that it will be possible to send via email by the end of the year.</p>                              | <p>Further comments on template to send to MM for consideration during optimisation</p> | <p>Comments to be forwarded to MM</p>             | <p>All</p>           | <p>Sep 15</p>               |
| 2015.05.08 | <b>Recommendations from York and Scarborough</b> | <p>Tocilizumab (Subcutaneous) – no change to current practice</p>   | <p>Approved</p>   | <p>No further action</p>                          |                      | <p>July 15</p>              |

| Agenda No  | Item   | Discussion   | Decision Made   | Action  | Lead   | Due Date/Date complete |
|------------|--|--|---|---|--|------------------------|
|            | <b>Commissioning Committee</b>                         | Tiotropium respimat for asthma – for routine commissioning at Step 4<br><br>Verteprofin photodynamic therapy – no change to current practice   | Approved<br><br>Approved  | Update Resp Guidelines<br><br>No further action   |  | Sep 15<br><br>July 15  |
| 2015.05.09 | <b>Shared Care Frameworks – Prescribing Guidelines</b> | <p>Chronic Pain Guidelines</p> <p>The guideline now includes more information and links but the recommended treatments remain the same. “consider early referral “ to be added to blue box. “Oxycodone “ to be added to equivalent dosing box. References to be altered as “*” “**” “+” proving confusing.</p> <p>Format needs to be improved as not all information fits on to page.</p> <p>Dr Miemie Kyaing would like more emphasis placed on early referral but the committee had concerns regarding the capacity of the service.</p> <p><b>Pain Leaflets</b> – Some members felt that one of the leaflets may not be appropriate for all patients but should still be made available</p> <p><b>Pain Referral Form</b> – The committee agreed to approve the form but GP’s would prefer to write letters as there are currently too many referral forms.</p> <p>Gabapentin/Pregabalin Guideline – “for Neuropathic Pain” to be added to guideline title.</p> <p>b) Dementia SCF – all 4 drugs Memantine, Galantamine, Donepezil and Rivastigmine have been incorporated into one SCF. To add line in responsibilities regarding baseline ECG</p> <p>The committee raised the issue that the Spire are still using old SCF, JLY will reiterate the need for</p> | <p>All pain guidelines and leaflets approved subject to amendments</p> <p>It was agreed that patients could be referred by GP letter or form.</p> <p>Approved subject to amendments”</p> <p>Jly to provide MM with contact from</p> | <p>Update documents</p> <p>WH to add documents to website</p> <p>Feedback to pain teams</p> | <p>MM</p> <p>GH, WC</p> <p>MM</p> <p>JLy</p> |                        |

| Agenda No | Item | Discussion  | Decision Made   | Action  | Lead  | Due Date/Date complete |
|-----------|------|---|---|---|---|------------------------|
|           |      | <p>using SCF from the website to the Spire and MM will add a Spire representative to the newsletter circulation list</p> <p>c)Blood Glucose Testing – The CSU medicines management team have written a proposal regarding blood glucose meters in line with a review written by Greater Manchester Medicines Management Committee. The paper evaluated all meters on overall service and clinical performance. The recommendations of the paper are currently just for Hull and it was agreed that Community pharmacy's would need to be given plenty of time to run down supplies of old meters. The companies providing the new meters have agreed they will work with practices to train staff in their use.</p> <p>d)Anticoagulation guidance/update Changes in line with NICE guidance and to include NOAC as first line option in AF, anticoagulation service is not available. CHCP teams will require further clarity on treatment choices and commissioned services. <b>Patient decision aid leaflet</b> – the committee decided that it would be appropriate to remove treatment costs from the leaflet before use.</p> <p>e)Lipid Guidelines – The committee agreed that the local guidance was only required for secondary prevention and that NICE guidance could be added to the website to cover treatment</p> | <p>Spire.</p> <p>Approved.</p> <p>Guidelines approved subject to amendments</p> <p>JLy to discuss with commissioners and feedback to CHCP.</p> <p>Guidelines approved subject to amendments</p> | <p>MM to make amendments</p> <p>J Ly to feedback to CHCP</p> <p>MM to make amendments</p> | <p>JLy</p> <p>JLy</p> <p>MM</p> <p>J Ly</p> <p>MM</p> |                        |

| Agenda No  | Item                                      | Discussion  | Decision Made                           | Action                                      | Lead | Due Date/Date complete |
|------------|---|---|---|---|------|------------------------|
|            |   | for primary prevention. The committee also agreed that Ezetimibe should be restricted to specialist advice only   |   |   |      |                        |
| 2015.05.10 | <b>Review of HERPC 2014/15</b>            | Discrepancies were noted in the attendance document, WH to review. Terms of reference need to be reviewed but it was agreed this would take place in November due to lack of GP CCG prescribing leads. Therefore current ToF R will remain in place until then. | .ToR approved in interim, until Nov 15. | WH to review attendance list and send again | WH   | July 15                |
| 2015.05.11 | <b>Correspondence Received</b>            | Formoterol/Citalopram interaction – this interaction is currently displaying on the EMIS system. However the interaction is not listed in the BNF and the committee agreed it had no clinical significance as it was purely theoretical.                        | CSU to write to GP's re this issue      |   | JLy  | July 15                |
| 2015.05.12 | <b>Additional Minutes for Information</b> | <ul style="list-style-type: none"> <li>a) MMIG (March)</li> <li>b) HEY D&amp;T (March, April)</li> <li>c) HFT DTC (Feb)</li> <li>d) Formulary Sub Group (April)</li> </ul>  | Noted                                   | No further action                           |      | May 15                 |
| 2015.05.13 | <b>AOB</b>                                | The LMC requested that they would like to be able to circulate HERPC minutes to members, the committee agreed with this.  | Agreed                                  | No further action                           |      | May 15                 |
| 2015.05.14 | <b>Date and Time of Next Meeting</b>      | Wednesday 22nd July 2015 1 – 3pm<br>The Boardroom, Health House, Willerby   |   |   |      |                        |